Randomized phase II study of sorafenib with or without everolimus in patients with radioactive iodine refractory Hurthle cell thyroid cancer (HCC) (Alliance A091302/ ITOG 1706) Meeting Abstract
| Authors: | Sherman, E. J.; Foster, N. R.; Su, Y. B.; Shergill, A.; Ho, A. L.; Konda, B.; Ghossein, R. A.; Ganly, I.; Schwartz, G. K. |
| Abstract Title: | Randomized phase II study of sorafenib with or without everolimus in patients with radioactive iodine refractory Hurthle cell thyroid cancer (HCC) (Alliance A091302/ ITOG 1706) |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120603267 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.6076 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 6076 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
